Daklinza (daclatasvir) / BMS 
Welcome,         Profile    Billing    Logout  
 32 Diseases   5 Trials   5 Trials   1782 News 


«12...234567891011121314»
  • ||||||||||  Daklinza (daclatasvir) / BMS, Sovaldi (sofosbuvir) / Gilead
    THE ROAD TO ELIMINATION OF HEPATITIS C: COSTS PER CURE FALL TO US $32 PER PERSON. (Hynes Convention Center, Hall B) -  Sep 29, 2019 - Abstract #AASLD2019AASLD_782;    
    API costs for DAAs continue to fall, and, consequently, potential generic prices fall too. National Health departments need to be aware of these potential costs when negotiating lower prices for mass HCV elimination programs.
  • ||||||||||  Daklinza (daclatasvir) / BMS, Sovaldi (sofosbuvir) / Gilead
    Journal, HEOR:  Economic Evaluation of Direct-Acting Antivirals for Hepatitis C in Norway. (Pubmed Central) -  Sep 26, 2019   
    For each of the hepatitis C genotypes 1, 2 and 3, there were combinations of DAAs that were cost effective in a Norwegian setting. As a result of recent tender negotiations in Norway, treating all diagnosed patients with hepatitis C with the most cost-effective DAAs will result in lower total expenditure on these medications compared with 2015.
  • ||||||||||  Journal:  Direct-Acting Antivirals to Prevent Vertical Transmission of Viral Hepatitis C: When Is the Optimal Time to Treat? (Pubmed Central) -  Sep 26, 2019   
    As a result of recent tender negotiations in Norway, treating all diagnosed patients with hepatitis C with the most cost-effective DAAs will result in lower total expenditure on these medications compared with 2015. Data to determine the best treatment point along the pregnancy-pediatric continuum are limited; however, given the lack of human data for use of DAAs during pregnancy, low rate of VT, high rate of spontaneous pediatric clearance, and recent approval of DAAs for pediatric patients, treatment of chronically infected children seems to be the optimal strategy currently.
  • ||||||||||  Copegus (ribavirin) / Bausch Health, Daklinza (daclatasvir) / BMS, Sovaldi (sofosbuvir) / Gilead
    Clinical, Journal, Real-World Evidence:  Real-world effectiveness and safety of sofosbuvir plus daclatasvir with or without ribavirin for genotype 2 chronic hepatitis C in Taiwan. (Pubmed Central) -  Sep 20, 2019   
    The use of direct-acting antivirals for the treatment of HCV in patients with HCC listed for transplantation does not seem to be associated with an increased risk of tumor progression during the waiting list or recurrence after LT. SOF/DCV with or without ribavirin is highly effective and safe for patients with genotype 2 HCV infection in real-world experience in Taiwan.
  • ||||||||||  Daklinza (daclatasvir) / BMS
    Biomarker, Journal:  Pharmacogenetics of the anti-HCV drug sofosbuvir: a preliminary study. (Pubmed Central) -  Sep 18, 2019   
    Furthermore, we performed sub-analyses considering the anti-HCV concomitant drug and HCV genotype, identifying specific polymorphisms associated with GS-331007 plasma concentrations: ABCB1 3435 C>T and HNF4α975 C>G in patients treated with daclatasvir, ABCB1 2677 G>T with ledipasvir and ABCB1 3435 C>T, ABCB1 2677 G>T, ABCG2 421 C>A and ABCG2 1194 + 928 C>A with ribavirin. In this study we suggested sofosbuvir GS-331007 metabolite plasma levels were affected by variants in the ABCB1 and HNFα genes.
  • ||||||||||  Daklinza (daclatasvir) / BMS
    Journal:  Identification of a Novel Hepatitis C Virus Genotype from Punjab, India - Expanding Classification of Hepatitis C Virus into 8 Genotypes. (Pubmed Central) -  Sep 18, 2019   
    Despite presence of baseline RASs within the GT8 virus of all 4 patients (NS3: V36L, Q80K/R; NS5A: Q30S, Y93S), all patients achieved a sustained virologic response; two treated with sofosbuvir/velpatasvir/voxilaprevir for 8 weeks, one with sofosbuvir/ledipasvir plus ribavirin for 24 weeks and one with sofosbuvir plus daclatasvir for 12 weeks. The discovery of a novel HCV GT8 confirms the circulation of this newly identified lineage in the human population.
  • ||||||||||  Daklinza (daclatasvir) / BMS
    Journal:  Micro-electro-flow reactor (μ-EFR) system for ultra-fast arene synthesis and manufacture of daclatasvir. (Pubmed Central) -  Sep 17, 2019   
    This method was further extended to a new generation commercial batch synthetic route for continuous flow ultra-fast daclatasvir synthesis in 33.2 min. We envisage that this micro-electro-flow reactor (μ-EFR) system platform will substantially enable advances in continuous-μ-flow fine chemical manufacturing, multistep reaction sequences, reaction devising equipment, and real-time extraction.
  • ||||||||||  Review, Journal:  HCV therapy: no one to let behind. (Pubmed Central) -  Sep 4, 2019   
    New triple regimens have solved the issue of retreatment of the few patients who present failure to DAAs therapy. In the present review we describe the current HCV landscape that allows to cure nearly all HCV infected patients.
  • ||||||||||  tacrolimus / Generic Mfg., Daklinza (daclatasvir) / BMS
    SAFETY AND EFFICACY OF SOFOSBUVIR BASED REGIMENS IN HEPATITIS C VIRUS RECURRENCE POST LIVER TRANSPLANTATION (Poster Exhibition - Hall 7) -  Aug 18, 2019 - Abstract #UEGW2019UEGW_3046;    
    All patients who received (SOF/SIM) were on Tacrolimus or rapamune based immunosuppression Mean age of the studied patients was 52.5±7.9 years (range 28-68), mostly males (99.7%)... Sofosbuvir based combinations are safe and effective in the treatment of recurrent HCV after LT, especially when combined with another directly acting antiviral.
  • ||||||||||  paritaprevir/ritonavir (ABT-450/r) / AbbVie, Daklinza (daclatasvir) / BMS, Sovaldi (sofosbuvir) / Gilead
    STUDY OF THE RESPONSE AND SAFETY OF DIRECT ACTING ANTIVIRAL COMBINATION THERAPY IN HEPATITIS C VIRUS-RELATED CHILD-B LIVER CIRRHOSIS (Poster Exhibition - Hall 7) -  Aug 18, 2019 - Abstract #UEGW2019UEGW_3041;    
    In Child A patients, 260 had sofosbuvir (SOF)and daclatasvir (DAC) for 12 weeks,13 had SOF plus simeprevir (SIM) for 12 weeks and 2 had Ritonavir-Paritaprevir-Ombitasvir-Ribavirin for 12 weeks. Real-world results of generic DAAs combinations in Egyptian patients with chronic HCV-Child B were very safe and effective with SVR-12 (98.5%&86.7%) with very rare reported complications (0.01%,0.9%) in Child A&B, respectively.
  • ||||||||||  Daklinza (daclatasvir) / BMS, Sovaldi (sofosbuvir) / Gilead
    ASSESSMENT OF CARDIAC FUNCTIONS BEFORE AND AFTER TREATMENT OF EGYPTIAN CHRONIC HEPATITIS C PATIENTS USING DIRECTLY ACTING ANTIVIRALS (Poster Exhibition - Hall 7) -  Aug 18, 2019 - Abstract #UEGW2019UEGW_2128;    
    Patients with HCC should be properly evaluated prior to antiviral therapy with DAAs and followed up carefully during and after therapy. Treatment of chronic HCV infection using DAAs (Sofosbuvir, Daclatasvir, Ribavirin) has no clinicaly significant effect on cardiac functions.However, some sort of sub-clinical myocardial affection can occur for further analytical studies.
  • ||||||||||  paritaprevir/ritonavir (ABT-450/r) / AbbVie, Daklinza (daclatasvir) / BMS, Sovaldi (sofosbuvir) / Gilead
    COMPARATIVE STUDY FOR RETREATING PATIENTS WHO FAILED TO PRIOR SOFOSBUVIR/ DACLATASVIR REGIMEN: AN OPEN LABELED RANDOMIZED TRIAL (Poster Exhibition - Hall 7) -  Aug 18, 2019 - Abstract #UEGW2019UEGW_1303;    
    Eighty patients were randomly re-treated either by Sofosbuvir(400mg)/Daclatasvir(60mg)/ Simeprevir(150mg)/Ribavirin (SIM-group, n=40) versus Sofosbuvir(400mg) /Ombitasvir(25mg)/ Paritaprevir(150mg) /Ritonavir(100mg) /Ribavirin (OPr-group, n=40) for 12 weeks. Re-treating patients with previous NS5A failure is possible and safe with satisfactory results.
  • ||||||||||  Clinical, Review, Journal:  Treatment of hepatitis C: Results in real life. (Pubmed Central) -  Aug 15, 2019   
    Furthermore, because of the existing level of evidence, it is difficult to define optimal regimens based on real-world data (ie, treatment duration, when to include ribavirin and options for patients with cirrhosis). The real-life challenges of managing HIV-coinfected patients are also discussed showing the additional burden of avoiding drug-drug interactions between DAAs and antiretrovirals.
  • ||||||||||  Daklinza (daclatasvir) / BMS, Sovaldi (sofosbuvir) / Gilead
    Clinical, Journal:  Anti-E1E2 antibodies status prior therapy favors direct-acting antiviral treatment efficacy. (Pubmed Central) -  Aug 15, 2019   
    The presence of anti-E1E2 at treatment initiation is a predictive factor of SVR among patients treated with DAA and more likely among patients with low initial HCV viral load (<6log10). Absence of anti-E1E2 at baseline could predict DAA-treatment failure.
  • ||||||||||  velpatasvir (GS-5816) / Gilead, Daklinza (daclatasvir) / BMS
    Predictors of Response to Direct Acting Anti-Viral Therapy in Patients With Decompensated Hepatitis C Cirrhosis (Exhibit Halls 3 and 4 (Street Level)) -  Aug 8, 2019 - Abstract #ACG2019ACG_1099;    
    48 patients were CPT class B whereas 14 patients of CPT class C. Patients with MELD score 15 were 21 (33.8%), 28 (45.1%) and 13 (21.1%) in pre-treatment and 23 (37%), 30 (48.3%) and 9 (14.7%) in post-treatment period respectively. Post-treatment 34 patients (54.8%) turned into CTP class A, 25 (40.3%) and 3 (4.9%) remained in CTP class B & C. Factors associated with favorable prognosis were male sex, baseline albumin, bilirubin, MELD score, presence of ascites.
  • ||||||||||  Sunvepra (asunaprevir) / BMS, Daklinza (daclatasvir) / BMS, Sovaldi (sofosbuvir) / Gilead
    Clinical, Journal:  Antiviral therapy for HCV in hemophilia A patients with HIV-1 co-infection. (Pubmed Central) -  Aug 2, 2019   
    During DAA treatment, HIV RNA in all the patients was constantly suppressed, while CD4 counts showed no obvious change.The most common treatment-emergent adverse events were weakness and loss of appetite (generally mild). There was no evidence of an increased tendency of bleeding, and changes in response to replacement.DAA therapy offered a safe and well-tolerated management strategy for HIV/HCV co-infected patients with hemophilia A. An awareness of the potential drug-drug interactions (DDI) between DAA and combination antiretroviral therapy (cART) by clinicians is important for optimal management of co-infected patients.